Loading...
•
Jun 30, 2022
Theravance Q2 2022 Earnings Report
Reported financial results for the second quarter of 2022.
Key Takeaways
Theravance Biopharma reported its Q2 2022 financial results, highlighting YUPELRI's strongest quarter of sales to date and a potential NDA filing path for ampreloxetine in MSA patients with symptomatic nOH. The sale of TRELEGY ELLIPTA royalty interests to Royalty Pharma for over $1.5 billion enables debt elimination and a planned return of capital to shareholders.
YUPELRI delivered its strongest quarter of sales to date.
Ampreloxetine discussions with FDA create a path to an NDA filing in MSA patients with symptomatic nOH.
Closed the sale of TRELEGY ELLIPTA royalty interests to Royalty Pharma for over $1.5 billion in potential total value.
The sale enables an elimination of debt and sets up a planned return of capital to shareholders.
Theravance
Theravance
Forward Guidance
No forward guidance was provided in the report.